Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
On the afternoon of September 27, Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences gave an oral presentation and paper discussion on the results of the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally recurrent or metastatic…
Read More…